sruilk / Shutterstock.com
The US Court of Appeals for the Federal Circuit yesterday, March 6, refused to rehear a decision which found Allergan and the Saint Regis Mohawk Tribe’s patents for dry-eye treatment Restasis (cyclosporine ophthalmic emulsion) are invalid.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Allergan, Saint Regis Mohawk Tribe, en banc, Restasis, patent, tribal immunity, US Supreme Court, inter partes reviews, IPRs